Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas-Reference-Cited by-同舟云学术

Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas

Published:2019-07-23 Issue:5 Volume:25 Page:797-806
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Patel‐Hett Sunita¹^ORCID,Martin Erika J.²,Mohammed Bassem M.²³⁴,Rakhe Swapnil¹,Sun Pengling¹,Barrett John C.⁵,Nolte Melinda E.⁵,Kuhn Janice⁵^ORCID,Pittman Debra D.¹,Murphy John E.¹,Brophy Donald F.²^ORCID

Affiliation:

1. Rare Disease Research Unit Early Clinical Development, Pfizer Inc Cambridge MA USA

2. Coagulation Advancement Laboratory, Department of Pharmacotherapy & Outcomes Science Virginia Commonwealth University (VCU) Richmond VA USA

3. Department of Clinical Pharmacy, Faculty of Pharmacy Cairo University Cairo Egypt

4. Department of Pathology, Microbiology, and Immunology Vanderbilt University Medical Center Nashville TN USA

5. Division of Hematology/Oncology, Department of Internal Medicine VCU Richmond VA USA

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.13820

Reference31 articles.

1. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model

2. Emicizumab prophylaxis in hemophilia A with inhibitors;Oldenburg J;N Engl J Med,2017

3. Characterization of the inhibition of tissue factor in serum;Broze GJ;Blood,1987

4. Isolation of the tissue factor inhibitor produced by HepG2 hepatoma cells.

5. Isolation of the lipoprotein associated coagulation inhibitor produced by HepG2 (human hepatoma) cells using bovine factor Xa affinity chromatography

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring nonreplacement therapies’ impact on hemophilia and other rare bleeding disorders;Research and Practice in Thrombosis and Haemostasis;2024-05

2. The foundation for investigating factor XI as a target for inhibition in human cardiovascular disease;Journal of Thrombosis and Thrombolysis;2024-04-25

3. Recapitulating the immune system of hemophilia A patients with inhibitors using immunodeficient mice;Thrombosis Research;2024-03

4. Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B;Cochrane Database of Systematic Reviews;2024-02-27

5. Gene therapy for hemophilia, a clinical viewpoint;Journal of the Formosan Medical Association;2023-11